US Monkeypox (Mpox) Vaccines and Treatments Market Industry Trends and Forecast to 2034: Segmented by (Product, Buyer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$225.5 MnPlaceholder estimate
Estimate 2025$233.9 Mn34.7% of the global market
Projected 2034$324.4 Mn 38.7%Adds $90.5 Mn over 9 forecast years
CAGR 2025–20343.7%Faster than 19% of 180 Pharmaceuticals markets here
Key players5Companies profiled
US is 34.69% of the global market.
In North America, the largest is US (this report) at $233.9 Mn.
1 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Monkeypox (Mpox) Vaccines and Treatments Market Analysis Executive Summary
Mpox vaccines and treatments prevent and treat mpox, a virus that spread worldwide in recent outbreaks.
Key segments of the monkeypox (Mpox) Vaccines and Treatments market include product (Vaccines and Antivirals) and buyer (Governments and Stockpiles, NGOs and Hospitals).
US Monkeypox (Mpox) Vaccines and Treatments market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Monkeypox (Mpox) Vaccines and Treatments Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the monkeypox (Mpox) Vaccines and Treatments market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the monkeypox (Mpox) Vaccines and Treatments market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the monkeypox (Mpox) Vaccines and Treatments market.
Competitive Landscape for Monkeypox (Mpox) Vaccines and Treatments Market in the US
The monkeypox (Mpox) Vaccines and Treatments market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Monkeypox (Mpox) Vaccines and Treatments Market in the US
Monkeypox (Mpox) Vaccines and Treatments in the US: rules, payment and research
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 1 study on Monkeypox (Mpox) Vaccines and Treatments that is recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for monkeypox (Mpox) Vaccines and Treatments. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in the US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Product
4.2 By Buyer
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Bavarian Nordic
7.2 SIGA Technologies
7.3 Emergent BioSolutions
7.4 KM Biologics
7.5 Moderna
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The monkeypox (Mpox) Vaccines and Treatments market can be segmented based on various criteria, including product, buyer and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Monkeypox (Mpox) Vaccines and Treatments right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Monkeypox (Mpox) Vaccines and Treatments in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
How big is the Monkeypox (Mpox) Vaccines and Treatments market in the US?
Placeholder estimate: about $233.9 Mn in 2025, rising to about $324.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Monkeypox (Mpox) Vaccines and Treatments market in the US growing?
Placeholder estimate: about 3.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Monkeypox (Mpox) Vaccines and Treatments market report cover?
The report splits the market by product (Vaccines, Antivirals), buyer (Governments and Stockpiles, NGOs, Hospitals) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Monkeypox (Mpox) Vaccines and Treatments market?
Key players include Bavarian Nordic, SIGA Technologies, Emergent BioSolutions, KM Biologics and Moderna.
What is driving the Monkeypox (Mpox) Vaccines and Treatments market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the monkeypox (Mpox) Vaccines and Treatments market.
Who regulates Monkeypox (Mpox) Vaccines and Treatments in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Monkeypox (Mpox) Vaccines and Treatments are running in the US?
1 study is recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Monkeypox (Mpox) Vaccines and Treatments?
PubMed lists 37 papers on Monkeypox (Mpox) Vaccines and Treatments added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.